Dabrafenib Mesylate and Moxetumomab Pasudotox-tdfk
Determining the interaction of Dabrafenib Mesylate and Moxetumomab Pasudotox-tdfk and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: dabrafenib
Brand name: Tafinlar
Synonyms: Dabrafenib
Generic Name: moxetumomab pasudotox
Brand name: Lumoxiti
Synonyms: Moxetumomab pasudotox, Moxetumomab Pasudotox
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dabrafenib Mesylate-Moxetumomab pasudotox-tdfk Intravenous
- Dabrafenib Mesylate-Moxifloxacin
- Dabrafenib Mesylate-Moxifloxacin (Systemic)
- Dabrafenib Mesylate-Moxifloxacin Hydrochloride
- Dabrafenib Mesylate-Moxifloxacin Injection
- Dabrafenib Mesylate-Moxifloxacin Intravenous
- Moxetumomab Pasudotox-tdfk-Dacarbazine
- Moxetumomab Pasudotox-tdfk-Dacarbazine Intravenous, Injection
- Moxetumomab Pasudotox-tdfk-Daclatasvir
- Moxetumomab Pasudotox-tdfk-Daclatasvir Dihydrochloride
- Moxetumomab Pasudotox-tdfk-Daclizumab
- Moxetumomab Pasudotox-tdfk-Daclizumab Subcutaneous